Advertisement

Neurologische Komplikationen der Kollagenosen

  • Torsten Witte
  • Thomas Skripuletz
Chapter

Zusammenfassung

Zu den Kollagenosen zählen der systemische Lupus erythematodes, das Sjögren-Syndrom, die Sklerodermie und die Poly-/Dermatomyositis. Neurologische Komplikationen sowohl des zentralen als auch des peripheren Nervensystems sind bei den Kollagenosen häufig. Sie sind daher bei vielen neurologischen Erkrankungen Differenzialdiagnosen. In dem Kapitel werden die Symptome, die Diagnostik und die Therapie des systemischen Lupus erythematodes, des Sjögren-Syndroms und der Sklerodermie sowie die jeweiligen neurologischen Komplikationen dieser Krankheitsbilder vorgestellt.

Literatur

  1. Bertsias GK, Ioannidis JP, Aringer M, Bollen E, Bombardieri S, Bruce IN, Cervera R, Dalakas M, Doria A, Hanly JG, Huizinga TW, Isenberg D, Kallenberg C, Piette JC, Schneider M, Scolding N, Smolen J, Stara A, Tassiulas I, Tektonidou M, Tincani A, Buchem MA van, Vollenhoven R van, Ward M, Gordon C, Boumpas DT (2010) EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis 69:2074–2082CrossRefPubMedGoogle Scholar
  2. Daniels TE (1984) Labial salivary gland biopsy in Sjögren’s syndrome. Assessment as a diagnostic criterion in 362 suspected cases. Arthritis Rheum 27:147–156CrossRefPubMedGoogle Scholar
  3. Delalande S, Seze J de, Fauchais AL, Hachulla E, Stojkovic T, Ferriby D et al (2004) Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients. Medicine (Baltimore) 83:280–291CrossRefGoogle Scholar
  4. Farrell DA, Medsger TA Jr (1982) Trigeminal neuropathy in progressive systemic sclerosis. Am J Med 73:57–62CrossRefPubMedGoogle Scholar
  5. Fox RI (2005) Sjögren’s syndrome. Lancet 366:321–331CrossRefPubMedGoogle Scholar
  6. Gøransson LG, Herigstad A, Tjensvoll AB, Harboe E, Mellgren SI, Omdal R (2006) Peripheral neuropathy in primary sjogren syndrome: a population-based study. Arch Neurol 63:1612–1615CrossRefPubMedGoogle Scholar
  7. Hanly JG, Urowitz MB, Siannis F, Farewell V, Gordon C, Bae SC, Isenberg D, Dooley MA, Clarke A, Bernatsky S, Gladman D, Fortin PR, Manzi S, Steinsson K, Bruce IN, Ginzler E, Aranow C, Wallace DJ, Ramsey-Goldman R, Vollenhoven R van, Sturfelt G, Nived O, Sanchez-Guerrero J, Alarcón GS, Petri M, Khamashta M, Zoma A, Font J, Kalunian K, Douglas J, Qi Q, Thompson K, Merrill JT (Systemic Lupus International Collaborating Clinics) (2008) Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: results from an international inception cohort study. Arthritis Rheum 58:843–853Google Scholar
  8. Hanly JG, Urowitz MB, Su L, Bae SC, Gordon C, Wallace DJ, Clarke A, Bernatsky S, Isenberg D, Rahman A, Alarcón GS, Gladman DD, Fortin PR, Sanchez-Guerrero J, Romero-Diaz J, Merrill JT, Ginzler E, Bruce IN, Steinsson K, Khamashta M, Petri M, Manzi S, Dooley MA, Ramsey-Goldman R, Vollenhoven R van, Nived O, Sturfelt G, Aranow C, Kalunian K, Ramos-Casals M, Zoma A, Douglas J, Thompson K, Farewell V (Systemic Lupus International Collaborating Clinics) (2010) Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 69:529–535Google Scholar
  9. Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725CrossRefPubMedGoogle Scholar
  10. Jara LJ, Pacheco-Reyes H, Medina G, Angeles U, Cruz-Cruz P, Saavedra MA (2007) Prolactin levels are associated with lupus activity, lupus anticoagulant, and poor outcome in pregnancy. Ann N Y Acad Sci 1108:218–226CrossRefPubMedGoogle Scholar
  11. Jennings JE, Sundgren PC, Attwood J, McCune J, Maly P (2004) Value of MRI of the brain in patients with systemic lupus erythematosus and neurologic disturbance. Neuroradiology 46:15–21CrossRefPubMedGoogle Scholar
  12. Joven BE, Almodovar R, Carmona L, Carreira PE (2010) Survival, causes of death, and risk factors associated with mortality in Spanish systemic sclerosis patients: results from a single university hospital. Semin Arthritis Rheum 39:285–293CrossRefPubMedGoogle Scholar
  13. Kaul M, Erkan D, Sammaritano L, Lockshin MD (2007) Assessment of the 2006 revised antiphospholipid syndrome classification criteria. Ann Rheum Dis 66:927–930CrossRefPubMedPubMedCentralGoogle Scholar
  14. Kowal-Bielecka O, Landewé R, Avouac J, Chwiesko S, Miniati I, Czirjak L, Clements P, Denton C, Farge D, Fligelstone K, Földvari I, Furst DE, Müller-Ladner U, Seibold J, Silver RM, Takehara K, Toth BG, Tyndall A, Valentini G, Hoogen F van den, Wigley F, Zulian F, Matucci-Cerinic M (EUSTAR Co-Authors) (2009). EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR) Ann Rheum Dis 68:620–628Google Scholar
  15. Lee P, Bruni J, Sukenik S (1984) Neurological manifestations in systemic sclerosis (scleroderma). J Rheumatol 11:480–483PubMedGoogle Scholar
  16. Manger K, Manger B, Repp R, Geisselbrecht M, Geiger A, Pfahlberg A, Harrer T, Kalden JR (2002) Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus. Ann Rheum Dis 61:1065–1070CrossRefPubMedPubMedCentralGoogle Scholar
  17. Masi G, Annunziata P (2016) Sjogren’s syndrome and multiple sclerosis: two sides of the same coin? Autoimmun Rev 15:457–461CrossRefPubMedGoogle Scholar
  18. McClain MT, Heinlen LD, Dennis GJ, Roebuck J, Harley JB, James JA (2005) Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry. Nat Med 11:85–89CrossRefPubMedGoogle Scholar
  19. Meijer JM, Meiners PM, Vissink A, Spijkervet FK, Abdulahad W, Kamminga N, Brouwer E, Kallenberg CG, Bootsma H (2010) Effectiveness of rituximab treatment in primary Sjögren’s syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 62:960–968CrossRefPubMedGoogle Scholar
  20. Mitsikostas DD, Sfikakis PP, Goadsby PJ (2004) A meta-analysis for headache in systemic lupus erythematosus: the evidence and the myth. Brain 127:1200–1209CrossRefPubMedGoogle Scholar
  21. Mori K, Iijima M, Koike H, Hattori N, Tanaka F, Watanabe H et al (2005) The wide spectrum of clinical manifestations in Sjögren’s syndrome-associated neuropathy. Brain 128:2518–2534CrossRefPubMedGoogle Scholar
  22. Moser KL, Kelly JA, Lessard CJ, Harley JB (2009) Recent insights into the genetic basis of systemic lupus erythematosus. Genes Immun 10:373–379CrossRefPubMedPubMedCentralGoogle Scholar
  23. Muñoz LE, Lauber K, Schiller M, Manfredi AA, Herrmann M (2010) The role of defective clearance of apoptotic cells in systemic autoimmunity. Nat Rev Rheumatol 6:280–289CrossRefPubMedGoogle Scholar
  24. Pars K, Pul R, Schwenkenbecher P, Sühs KW, Wurster U, Witte T, Bronzlik P, Stangel M, Skripuletz T (2017) Cerebrospinal fluid findings in neurological diseases associated with Sjögren’s syndrome. Eur Neurol 77:91–102CrossRefPubMedGoogle Scholar
  25. Preliminary criteria for the classification of systemic sclerosis (scleroderma) (1980) Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 23:581–590CrossRefGoogle Scholar
  26. Radstake TR, Gorlova O, Rueda B, Martin JE, Alizadeh BZ, Palomino-Morales R, Coenen MJ, Vonk MC, Voskuyl AE, Schuerwegh AJ, Broen JC, Riel PL van, van ’t Slot R, Italiaander A, Ophoff RA, Riemekasten G, Hunzelmann N, Simeon CP, Ortego-Centeno N, González-Gay MA, González-Escribano MF; Spanish Scleroderma Group, Airo P, Laar J van, Herrick A, Worthington J, Hesselstrand R, Smith V, Keyser F de, Houssiau F, Chee MM, Madhok R, Shiels P, Westhovens R, Kreuter A, Kiener H, Baere E de, Witte T, Padykov L, Klareskog L, Beretta L, Scorza R, Lie BA, Hoffmann-Vold AM, Carreira P, Varga J, Hinchcliff M, Gregersen PK, Lee AT, Ying J, Han Y, Weng SF, Amos CI, Wigley FM, Hummers L, Nelson JL, Agarwal SK, Assassi S, Gourh P, Tan FK, Koeleman BP, Arnett FC, Martin J, Mayes MD (2010) Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat Genet 42:426–429CrossRefPubMedPubMedCentralGoogle Scholar
  27. Rihl M, Ulbricht K, Schmidt RE, Witte T (2009) Treatment of sicca symptoms with hydroxychloroquine in patients with Sjogren’s syndrome. Rheumatology 48:796–799CrossRefPubMedGoogle Scholar
  28. Schady W, Sheard A, Hassell A, Holt L, Jayson MI, Klimiuk P (1991) Peripheral nerve dysfunction in scleroderma. Q J Med 80:661–675PubMedGoogle Scholar
  29. Seze J de, Devos D, Castelnovo G, Labauge P, Dubucquoi S, Stojkovic T, Ferriby D, Vermersch P (2001) The prevalence of Sjögren syndrome in patients with primary progressive multiple sclerosis. Neurology 57:1359–1363CrossRefPubMedGoogle Scholar
  30. Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, Rasmussen A, Scofield H, Vitali C, Bowman SJ, Mariette X, International Sjögren’ Syndrome Criteria Working Group 2016 (2017) American College of Rheumatology/European League Against Rheumatism Classification criteria for Primary Sjögren’s syndrome. Arthritis Rheum 69:35–45Google Scholar
  31. Smith V, Vanthuyne M, Vander Cruyssen B, Van Praet J, Vermeiren F, Smets H, Houssiau F, De Keyser F (2008) Over-representation of construction-related occupations in male patients with systemic sclerosis. Ann Rheum Dis 67:1448–1450CrossRefPubMedGoogle Scholar
  32. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277CrossRefPubMedGoogle Scholar
  33. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 42:599–608Google Scholar
  34. Tokunaga M, Saito K, Kawabata D, Imura Y, Fujii T, Nakayamada S, Tsujimura S, Nawata M, Iwata S, Azuma T, Mimori T, Tanaka Y (2007) Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 66:470–475CrossRefPubMedGoogle Scholar
  35. Tyndall AJ, Bannert B, Vonk M, Airò P, Cozzi F, Carreira PE, Bancel DF, Allanore Y, Müller-Ladner U, Distler O, Iannone F, Pellerito R, Pileckyte M, Miniati I, Ananieva L, Gurman AB, Damjanov N, Mueller A, Valentini G, Riemekasten G, Tikly M, Hummers L, Henriques MJ, Caramaschi P, Scheja A, Rozman B, Ton E, Kumánovics G, Coleiro B, Feierl E, Szucs G, Von Mühlen CA, Riccieri V, Novak S, Chizzolini C, Kotulska A, Denton C, Coelho PC, Kötter I, Simsek I, Lefebvre PGP de la, Hachulla E, Seibold JR, Rednic S, Stork J, Morovic-Vergles J, Walker UA (2010) Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 69:1809–1815CrossRefPubMedGoogle Scholar
  36. Uramoto KM, Michet CJ Jr, Thumboo J, Sunku J, O’Fallon WM, Gabriel SE (1999) Trends in the incidence and mortality of systemic lupus erythematosus, 1950–1992. Arthritis Rheum 42:46–50CrossRefGoogle Scholar
  37. Versura P, Frigato M, Cellini M, Mulè R, Malavolta N, Campos EC (2007) Diagnostic performance of tear function tests in Sjogren’s syndrome patients. Eye 21:229–237CrossRefPubMedGoogle Scholar
  38. Wandinger KP, Stangel M, Witte T, Venables P, Charles P, Jarius S, Wildemann B, Probst C, Iking-Konert C, Schneider M (2010) Autoantibodies against aquaporin-4 in patients with neuropsychiatric systemic lupus erythematosus and primary Sjögren’s syndrome. Arthritis Rheum 62:1198–1200CrossRefPubMedGoogle Scholar
  39. Weiner SM, Otte A, Schumacher M, Klein R, Gutfleisch J, Brink I, Otto P, Nitzsche EU, Moser E, Peter HH (2000) Diagnosis and monitoring of central nervous system involvement in systemic lupus erythematosus: value of F-18 fluorodeoxyglucose PET. Ann Rheum Dis 59:377–385CrossRefPubMedPubMedCentralGoogle Scholar
  40. Wernicke D, Hess H, Gromnica-Ihle E, Krause A, Schmidt WA (2008) Ultrasonography of salivary glands – a highly specific imaging procedure for diagnosis of Sjögren’s syndrome. J Rheumatol 35:285–293PubMedGoogle Scholar
  41. Witte T, Bierwirth J, Schmidt RE, Matthias T (2006) Antibodies against alpha-fodrin are associated with dry eyes and mouth in the general population. J Rheumatol 33:1713PubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Klinische Immunologie und RheumatologieMedizinische Hochschule HannoverHannoverDeutschland
  2. 2.Klinik für NeurologieMedizinische Hochschule HannoverHannoverDeutschland

Personalised recommendations